Pharmacoeconomic evaluation of camrelizumab combined with chemotherapy in the treatment of cervical cancer in China

YANG Songtian; YAN Bo

doi:10.6039/j.issn.1001-0408.2025.14.13

您当前的位置：

首页 >

文章列表页 >

Pharmacoeconomic evaluation of camrelizumab combined with chemotherapy in the treatment of cervical cancer in China

更新时间：2025-09-24

- Pharmacoeconomic evaluation of camrelizumab combined with chemotherapy in the treatment of cervical cancer in China
- ZHONGGUO YAOFANG Vol. 36, Issue 14, Pages: 1765-1769(2025)
- 作者机构：
  
  重庆医科大学公共卫生学院，重庆　400016
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.14.13
  CLC： R956
- Received：08 November 2024，
  
  Revised：2025-05-19，
  
  Accepted：26 June 2025，
  
  Published：30 July 2025
- 稿件说明：
移动端阅览
杨颂恬,严波.卡瑞利珠单抗联合化疗用于我国宫颈癌患者的药物经济学评价[J].中国药房,2025,36(14):1765-1769.

YANG Songtian,YAN Bo.Pharmacoeconomic evaluation of camrelizumab combined with chemotherapy in the treatment of cervical cancer in China[J].ZHONGGUO YAOFANG,2025,36(14):1765-1769.
杨颂恬,严波.卡瑞利珠单抗联合化疗用于我国宫颈癌患者的药物经济学评价[J].中国药房,2025,36(14):1765-1769. DOI： 10.6039/j.issn.1001-0408.2025.14.13.

YANG Songtian,YAN Bo.Pharmacoeconomic evaluation of camrelizumab combined with chemotherapy in the treatment of cervical cancer in China[J].ZHONGGUO YAOFANG,2025,36(14):1765-1769. DOI： 10.6039/j.issn.1001-0408.2025.14.13.

摘要

目的

对卡瑞利珠单抗联合化疗用于我国宫颈癌患者的经济性进行评价。

方法

从中国卫生体系角度出发，基于卡瑞利珠单抗联合化疗治疗宫颈癌的文献资料构建Markov模型，其中不良反应发生情况通过Meta分析获得。设置研究时限为10年，循环周期为3周。成本包括药品成本、不良反应治疗成本等直接成本，效用值参考现有研究，转移概率基于文献数据计算，贴现率为5%，意愿支付（WTP）阈值采用3倍我国2024年人均国内生产总值（GDP）即287 247元/质量调整生命年（QALY），比较卡瑞利珠单抗联合或不联合化疗的经济性，并通过单因素敏感性分析和蒙特卡罗模拟评估参数波动对结果的影响。

结果

与单用卡瑞利珠单抗方案比较，卡瑞利珠单抗联合化疗方案的增量成本-效果比为181 507.58元/QALY，小于本研究设定的WTP阈值。单因素分析结果显示，两组无进展生存状态到死亡的转移概率对结果的影响较大；概率敏感性分析结果表明，以3倍我国2024年人均GDP为WTP阈值时，卡瑞利珠单抗联合化疗方案具有经济性的概率为 91.8%。

结论

从中国卫生体系角度出发，与单用卡瑞利珠单抗方案比较，当以3倍我国2024年人均GDP为WTP阈值时，卡瑞利珠单抗联合化疗用于我国宫颈癌患者具有经济性。

Abstract

OBJECTIVE

To perform a pharmacoeconomic evaluation of camrelizumab combined with chemotherapy in the treatment of cervical cancer in China.

METHODS

From the perspective of China’s healthcare system， a Markov model was constructed based on literature data regarding the treatment of cervical cancer with camrelizumab combined with chemotherapy， where the incidence of adverse reactions was obtained through a meta-analysis. The model was run over a 10-year time horizon with a 3-week cycle length. Costs included direct costs （e.g. drug cost， adverse event treatment cost）. Utility values were derived from existing studies， and transition probabilities were calculated using literature data， with a discount rate of 5%； the willingness-to-pay （WTP） threshold was set at 3 times China’s 2024 per capita gross domestic product （GDP）， i.e. 287 247 yuan/quality-adjusted life year（QALY）. Cost-effectiveness was compared between camrelizumab combined with chemotherapy and monotherapy. One-way sensitivity analysis and Monte Carlo simulation were used to evaluate the impact of parameter variations on results.

RESULTS

Compared with camrelizumab monotherapy， the incremental cost-effectiveness ratio （ICER） of camrelizumab combined with chemotherapy was 181 507.58 yuan/QALY， below the predefined WTP threshold. One-way sensitivity analysis showed that the outcomes were largely affected by the progression-free survival-to-death transition probabilities in both groups. Probabilistic sensitivity analysis indicated a 91.8% probability of camrelizumab combined with chemotherapy being cost-effective at a WTP threshold of 3 times China’s 2024 per capita GDP.

CONCLUSIONS

From China’s healthcare system perspective， camrelizumab combined with chemotherapy is cost-effective for cervical cancer in China， compared with monotherapy， when using 3 times China’s 2024 per capita GDP as the WTP threshold.

关键词

Keywords

references

BRAY F ， LAVERSANNE M ， SUNG H ， et al . Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2024 ， 74 （ 3 ）： 229 - 263 .

HAN B F ， ZHENG R S ， ZENG H M ， et al . Cancer incidence and mortality in China，2022 [J ] . J Natl Cancer Cent ， 2024 ， 4 （ 1 ）： 47 - 53 .

张力忆，蒋奉希，桂定清 . 贝伐珠单抗联合紫杉醇+卡铂治疗持续性或复发性宫颈癌的临床观察 [J ] . 中国药房， 2024 ， 35 （ 17 ）： 2126 - 2130 .

张军 . 宫颈癌治疗的现状及问题：从临床指南到真实世界研究 [J ] . 中国全科医学， 2022 ， 25 （ 3 ）： 259 - 263 .

王思渊，鲁辉，杨纯 . PD-1/PD-L1类单抗药物在肿瘤治疗中的应用进展 [J ] . 中国生物制品学杂志， 2023 ， 36 （ 1 ）： 105 - 111，118 .

HUANG X ， HE M J ， PENG H Y ， et al . Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy：a secon-dary analysis of the CLAP trial [J ] . J Immunother Cancer ， 2021 ， 9 （ 5 ）： e002223 .

RAMAKRISHNAN R ， GABRILOVICH D I . Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer [J ] . Cancer Immunol Immunother ， 2011 ， 60 （ 3 ）： 419 - 423 .

卓青婵，朱敏莹，左瑜芳，等 . 国产PD-1抑制剂在妇科肿瘤中的研究现状 [J ] . 临床医学研究与实践， 2024 ， 9 （ 8 ）： 184 - 190 .

LI K Z ， CHEN J ， HU Y J ， et al . Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer（NACI study）：a multicentre，single-arm，phase 2 trial [J ] . Lancet Oncol ， 2024 ， 25 （ 1 ）： 76 - 85 .

刘国恩，吴晶，谢锋 . 中国药物经济学评价指南导读：2022 [M ] . 北京：中国市场出版社出版， 2022 ： 63 - 69 .

叶子平，马佳，刘抚瑶，等 . 以1～3倍人均GDP作为药物经济学阈值的文献溯源及概念分析 [J ] . 中国卫生经济， 2020 ， 39 （ 5 ）： 72 - 75 .

ZHANG X L ， CHEN J L ， LIU N F ， et al . Camrelizumab（SHR-1210）with carboplatin and albumin-binding paclitaxel in patients with metastatic or recurrent cervical cancer：an open-label，phase 2 trial [J ] . J Cancer Res Ther ， 2022 ， 18 （ 2 ）： 482 - 487 .

沈静，张丽华，徐晶晶，等 . 卡瑞利珠单抗联合白蛋白结合型紫杉醇对晚期宫颈癌患者肿瘤标志物、免疫功能和血管新生指标的影响 [J ] . 现代生物医学进展， 2024 ， 24 （ 13 ）： 2592 - 2595 .

JIAN X L ， ZHANG J J ， HUANG Y ， et al . Early salvage therapy with anti-PD-1 antibody camrelizumab in patients with advanced cervical cancer：a retrospective study [J ] . Clin Transl Oncol ， 2025 ， 27 （ 2 ）： 693 - 698 .

CHEN J ， LI K Z ， HU Y J ， et al . Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer（NACI study）：a prospective，single-arm，phase Ⅱ trial [J ] . BMJ Open ， 2023 ， 13 （ 5 ）： e067767 .

CHEN J ， LI K ， HAN Y ， et al . 560P Neoadjuvant camre-lizumab plus chemotherapy in patients with locally advanced cervical cancer（NACI）：a prospective，single-arm，phase Ⅱ trial [J ] . Ann Oncol ， 2022 ， 33 ： S804 .

王翠，李亚玲 . PD-1抑制剂联合全身化疗治疗复发转移性宫颈癌的临床效果观察 [J ] . 临床误诊误治， 2024 ， 37 （ 2 ）： 76 - 81 .

WANG Y Z ， WANG J S ， DU J ， et al . Clinical benefit analysis of PD-1 inhibitors in patients with advanced，recurrent or metastatic cervical cancer：a meta-analysis and systematic review [J ] . Front Immunol ， 2024 ， 15 ： 1305810 .

PETITTI D B . Meta-analysis，decision analysis，and cost-effectiveness analysis [M ] . 2nd ed . Oxford ： Oxford University Press ， 1999 ： 178 - 181 .

ZHENG Z W ， SONG X B ， QIU G D ， et al . Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China [J ] . Curr Med Res Opin ， 2023 ， 39 （ 3 ）： 433 - 440 .

CHEN M L ， ZHANG H ， HE X Y ， et al . Cost-effectiveness of utidelone and capecitabine versus monotherapy in anthracycline- and taxane-refractory metastatic breast cancer [J ] . Front Pharmacol ， 2024 ， 15 ： 1303808 .

CHEN P Y ， FU C ， SHEN L ， et al . Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma [J ] . BMC Health Serv Res ， 2024 ， 24 （ 1 ）： 676 .

ZHAO Z Y ， CHEN T F ， ZHOU Z ， et al . Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China [J ] . BMJ Open ， 2023 ， 13 （ 12 ）： e071832 .

YANG X L ， ZHENG X C ， HU S ， et al . Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma：a cost-effectiveness analysis based on network meta-analysis [J ] . BMC Cancer ， 2024 ， 24 （ 1 ）： 654 .

HUO G W ， LIU W J ， CHEN P . Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer [J ] . J Gynecol Oncol ， 2024 ， 35 （ 5 ）： e58 .

杨一玖，张海力，梁宁，等 . 国内外中成药药物经济学研究的系统评价及质量评估 [J ] . 中国循证医学杂志， 2023 ， 23 （ 9 ）： 1053 - 1059 .

张雨馨，楼寒梅，吕晓娟，等 . 卡瑞利珠单抗治疗复发或晚期子宫恶性肿瘤患者的疗效和安全性评价 [J/OL ] . 中华危重症医学杂志（电子版）， 2021 ， 14 （ 2 ）： 127 - 132 （ 2021-07-02 ）[ 2024-12-22 ] . https：//d.wanfangdata.com.cn/periodical/ChVQZXJpb2RpY2FsQ0hJMjAyNTA2MjISE-npod3p6eXh6ejIwMjEwMjAwNhoIeHM0OWhuYnY%3D. DOI： 10.3877/cma.j.issn.1674-6880.2021.02.006 https://d.wanfangdata.com.cn/periodical/ChVQZXJpb2RpY2FsQ0hJMjAyNTA2MjISE-npod3p6eXh6ejIwMjEwMjAwNhoIeHM0OWhuYnY%3D.DOI:10.3877/cma.j.issn.1674-6880.2021.02.006 .

GIBSON E J ， BEGUM N ， KOBLBAUER I ， et al . Economic evaluation of single versus combination immuno-oncology therapies：application of a novel modelling approach in metastatic melanoma [J ] . Clinicoecon Outcomes Res ， 2020 ， 12 ： 241 - 252 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-utility analysis of bevacizumab combined with erlotinib in the first-line treatment of advanced EGFR mutant non-squamous NSCLC

Systematic review of pharmacoeconomic evaluation on PCSK9 inhibitors for the prevention of cardiovascular disease in patients with hypercholesterolemia

Cost-utility analysis of pembrolizumab combined with chemotherapy in the first-line treatment of advanced or unresectable biliary tract carcinoma

Research on merging methods and influencing factors of health state disutility values estimation ：taking diarrhea caused by antitumor drugs as an example

Pharmacoeconomic evaluation of Qili qiangxin capsule in the treatment of chronic heart failure

Related Author

SHEN Aizong

ZHANG Xiaohan

LU Luolan

ZHAO Yingying

JU Wenxiang

ZHOU Jiancheng

WANG Yongqing

CHEN Pingyu

Related Institution

College of Pharmacy， Anhui University of Chinese Medicine

Anhui Province Medicines Clinical Comprehensive Evaluation Technology Center

Anhui Provincial Key Laboratory of Precision Pharmaceutical Preparation and Clinical Pharmacy

Anhui Provincial Key Laboratory of Philosophy and Social Sciences for Public Health and Social Governance

Discipline Key Laboratory for Key Technology Research and Clinical Application of Mass Spectrometry Jointly Constructed by Anhui Province

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰